DCI releases fourteenth edition of its highly regarded industry analysis
PHILADELPHIA, Oct. 10, 2023 /PRNewswire-PRWeb/ -- Today Drug Channels Institute (DCI) released its exclusive analysis of U.S. prescription drug distribution channels. DCI's new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors delves into the business operations and industry environment of the Big Three public drug wholesalers—AmerisourceBergen/Cencora, Cardinal Health, and McKesson.
"We project that drug distribution revenues for the Big Three public companies—AmerisourceBergen (Cencora), Cardinal Health, and McKesson—will reach $700 billion for 2023," says Drug Channels Institute CEO Adam J. Fein, Ph.D., the study's author and a widely regarded expert on pharmaceutical economics and the drug distribution system. "Wholesalers' U.S. drug distribution revenues are growing at double-digit rates, driven by the post-pandemic bounce back in U.S. healthcare, booming utilization of new anti-obesity GLP-1 agonist medications, and shifts in procurement strategies by some large pharmacy customers."
This unique, encyclopedic resource analyzes the crucial healthcare trends that will affect wholesale distribution of prescription pharmaceuticals. Now in its 14th edition, The 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors offers 163 proprietary charts, exhibits, and data tables. It remains the most comprehensive resource for analyzing the pharmaceutical distribution industry's economics, market structure, growth rates, forces of change, and interactions within the U.S. healthcare system. The new report also provides an updated analysis of each of the Big Three public companies' business segments and underlying profitability, based upon DCI's proprietary economic models.
"Biosimilars of provider-administered specialty drugs are now an important source of profits for wholesalers and specialty distributors," Fein adds. "The biosimilar market has continued to expand as adoption grows, prices decline, and payers relax formulary limits."
About Drug Channels Institute
Drug Channels Institute is a leading source of industry research about pharmaceutical economics and the drug distribution system. To learn more about its products, visit www.drugchannelsinstitute.com. Access Dr. Fein's popular Drug Channels blog at www.drugchannels.net.
SOURCE Drug Channels Institute